On behalf of the UK Liver and Cardiothoracic Audit Steering Groups.
Comparison of the Incidence of Malignancy in Recipients of Different Types of Organ: A UK Registry Audit
Article first published online: 23 JUL 2010
©2010 The Authors Journal compilation©2010 The American Society of Transplantation and the American Society of Transplant Surgeons
American Journal of Transplantation
Volume 10, Issue 8, pages 1889–1896, August 2010
How to Cite
Collett, D., Mumford, L., Banner, N. R., Neuberger, J. and Watson, C. (2010), Comparison of the Incidence of Malignancy in Recipients of Different Types of Organ: A UK Registry Audit. American Journal of Transplantation, 10: 1889–1896. doi: 10.1111/j.1600-6143.2010.03181.x
- Issue published online: 23 JUL 2010
- Article first published online: 23 JUL 2010
- Received 11 February 2010, revised 23 April 2010 and accepted for publication 12 May 2010
- nonmelanoma skin cancer;
- organ donation;
- standardized incidence ratio
An increased incidence of malignancy is an established complication of organ transplantation and the associated immunosuppression. In this study on cancer incidence in solid organ transplant recipients in Britain, we describe the incidence of de novo cancers in the allograft recipient, and compare these incidences following the transplantation of different organs. Data in the UK Transplant Registry held by NHS Blood and Transplant (NHSBT) were linked with data made available by the cancer registries in England, Scotland and Wales. Incidence rates in the transplanted population were then compared with the general population, using standardized incidence ratios matched for age, gender and time period. The 10-year incidence of de novo cancer in transplant recipients is twice that of the general population, with the incidence of nonmelanoma skin cancer being 13 times greater. Nonmelanoma skin cancer, cancer of the lip, posttransplant lymphoproliferative disease and anal cancer have the largest standardized incidence ratios, but the incidence of different types of malignancy differs according to the organ transplanted. Patterns in standardized incidence ratios over time since transplantation are different for different types of transplant recipient, as well as for different malignancies. These results have implications for a national screening program.